Notably, a recent study analysing patients with ccRCC enrolled in nivolumab clinical trials revealed that patients with a mutation in PBRM1 showed improved survival rates after nivolumab treatment. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.